NJ Biotech Says One of Its Products Shows Promise As COVID-19 Treatment

Preclinical experiments involving a compound developed by Tyme Technologies Inc. show that the product may be an effective therapy for COVID-19, the Bedminster-based biotech announced Aug. 26.

The company said in a statement that initial testing of an antiviral bile acid on one of its cancer treatments “demonstrated an impact on COVID-19.” Tyme added it joined with Massachusetts General Hospital and Weill Cornell Medical Center to design a proof of concept trial with recently diagnosed, symptomatic patients. If the results of the trial are positive, the company could embark on a development program of the compound, dubbed TYME-19, as a potential oral treatment for patients with COVID-19 before they are hospitalized or as protection for high-risk individuals and front-line health care workers.

Read more…